April 24, 2026 – Dr. William Chen, Chairman of Lishan Biotech, has added another honor to his name. At the 2025 Pudong New Area “Pearl Cup” Entrepreneurship Competition, Dr. Chen and his team won the “Most Promising Overseas Returnee Entrepreneurship Team Award” for their project, the “World-Class Live Biotherapeutic Product (LBP) Platform for Gut Microbiome.”

The competition was hosted by Pudong Venture Capital Group and guided by the Pudong New Area Talent Work Bureau. It aimed to attract overseas and domestic tech talent entrepreneurship projects through a model of “competition-based evaluation and investment linkage.” Focusing on three leading industries—integrated circuits, biomedicine, and artificial intelligence—the competition drew numerous projects from home and abroad. Over 70% of the participating entrepreneurs had overseas study or work experience. After multiple rounds of rigorous evaluation, Dr. Chen’s team stood out with their originality and industrialization potential, earning high recognition from the jury.

AI-Empowered Innovation: Deepening Frontiers in Microbiome Therapeutics

Lishan Biotech is a biopharmaceutical company dedicated to AI-powered R&D of live biotherapeutic products and small-molecule innovative drugs. By developing next-generation microbiome-based therapies, the company addresses hundreds of billions of dollars of unmet clinical needs worldwide in areas such as inflammation, oncology, and neurological disorders. Lishan aims to become an indispensable hub in the microbiome therapy field, systematically expanding the boundaries of microbiome treatment.

This award not only highly recognizes Dr. William Chen and his team’s sustained commitment to innovative drug development but also fully affirms Lishan Biotech’s dual-engine strategy of “AI + Microbiome,” its globally proprietary Swarming colonization technology, and the industrialization potential of its Intelligent Microbiome Application Platform (IMicAP).

Going forward, Lishan Biotech will continue to build a globally competitive portfolio of microbiome therapies, contributing cutting-edge solutions to human health.